Rezdiffra (Resmetirom) and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up in Clinical Practice

Resmetirom (brand name Rezdiffra) received FDA approval in March 2024 as the first drug indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced hepatic fibrosis (stages F2 and F3) [1]. Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, is prescribed for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension [2]. The overlap is predictable: MASH disproportionately affects men over 40 with metabolic syndrome, and erectile dysfunction shares the same risk-factor profile.

The Metabolic Syndrome Connection

Approximately 30% of adults with type 2 diabetes have concurrent MASH, and erectile dysfunction prevalence in diabetic men exceeds 50% according to a meta-analysis of 145 studies (N=88,577) published in Diabetic Medicine [3]. A prescriber managing a MASH patient on resmetirom will frequently encounter tadalafil on the medication list. That makes this interaction question clinically common, even though neither drug label specifically addresses it.

What the FDA Labels Say

The Rezdiffra prescribing information identifies CYP2C8 substrates (such as repaglinide) and OATP1B3 substrates (such as rosuvastatin) as drugs whose exposure may increase during co-administration [1]. Tadalafil appears on neither list. The Cialis/tadalafil label flags strong CYP3A4 inhibitors (ketoconazole, ritonavir) and inducers (rifampin) as interaction concerns [2]. Resmetirom is not classified as either.

Pharmacokinetic Analysis: CYP3A4, CYP2C8, and Transporter Pathways

The interaction potential between two drugs depends on whether one alters the absorption, distribution, metabolism, or elimination of the other. Both resmetirom and tadalafil rely on CYP3A4 as their primary metabolic enzyme, but sharing a metabolic pathway does not automatically produce a clinically meaningful interaction [4].

Resmetirom's Enzyme and Transporter Profile

In vitro and clinical pharmacology data from the Rezdiffra label show that resmetirom is a substrate of CYP3A4, CYP2C8, and organic anion transporting polypeptides OATP1B1 and OATP1B3 [1]. At therapeutic concentrations (80 mg or 100 mg daily, dosed by body weight), resmetirom acts as a weak inhibitor of CYP2C8 and OATP1B3. It does not inhibit CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant exposures [1].

This is the central pharmacokinetic point. Because resmetirom does not inhibit CYP3A4, it will not increase tadalafil plasma concentrations the way ketoconazole does. A study of ketoconazole 400 mg daily with tadalafil 20 mg increased tadalafil AUC by 312% [2]. No analogous effect is expected with resmetirom.

Tadalafil's Metabolic Fate

Tadalafil is metabolized predominantly by CYP3A4 to a catechol metabolite that is then glucuronidated [2]. It is not a CYP2C8 substrate, so resmetirom's weak CYP2C8 inhibition is irrelevant to tadalafil clearance. Tadalafil is also not a meaningful inhibitor or inducer of CYP3A4, meaning it will not alter resmetirom's metabolism in the reverse direction [2].

Transporter Considerations

Resmetirom is an OATP1B1/1B3 substrate and a weak OATP1B3 inhibitor [1]. Tadalafil disposition does not depend on OATP transporters, so this pathway is unlikely to contribute to an interaction. P-glycoprotein (P-gp) also does not appear to be a significant factor for either drug at standard doses.

Pharmacodynamic Overlap: Where Clinical Caution Applies

The absence of a pharmacokinetic interaction does not eliminate all risk. Two drugs can still produce additive or overlapping pharmacodynamic effects.

Shared Adverse Effects

In the MAESTRO-NASH trial (N=966), the most common adverse events with resmetirom 100 mg were diarrhea (33.0% vs. 16.8% placebo), nausea (22.2% vs. 8.6%), and headache (8.4% vs. 6.4%) [5]. Tadalafil's most frequently reported adverse effects include headache (15%), dyspepsia (10%), back pain (6%), and flushing (3%) at the 20 mg dose [2].

Headache occurs with both drugs. For patients who experience headache on resmetirom alone, adding tadalafil could increase headache frequency or severity. This is manageable but should be discussed with patients before co-prescribing.

Cardiovascular and Hemodynamic Effects

Resmetirom's thyroid hormone receptor beta selectivity was designed to avoid the cardiovascular risks associated with non-selective thyroid hormone analogs. In the MAESTRO-NASH trial, resmetirom did not increase heart rate or cause clinically significant QTc prolongation at the 100 mg dose [5]. The drug did reduce LDL cholesterol by approximately 14% and triglycerides by approximately 20%, effects mediated through hepatic lipid metabolism rather than systemic hemodynamics [5].

Tadalafil produces mild systemic vasodilation and can lower systolic blood pressure by 1 to 4 mmHg on average [2]. The absolute contraindication is concurrent nitrate use, where PDE5 inhibition combined with nitric oxide donor activity produces dangerous hypotension [2]. Resmetirom is not a nitrate, does not donate nitric oxide, and does not produce clinically relevant blood pressure changes. This combination does not carry a hypotensive risk analogous to the nitrate-PDE5 inhibitor interaction.

Hepatic Function in MASH Patients

This is the most underappreciated clinical variable. MASH with F2-F3 fibrosis indicates meaningful hepatic architectural change. While resmetirom was studied specifically in this population and does not require dose reduction for moderate hepatic impairment (Child-Pugh B) [1], the Cialis label recommends that tadalafil dose not exceed 10 mg once daily in patients with mild to moderate hepatic impairment (Child-Pugh A or B) [2].

Most MASH-F2/F3 patients have preserved synthetic function and would not meet formal Child-Pugh criteria for impairment. But fibrosis can reduce sinusoidal blood flow and alter CYP3A4 expression in zone 3 hepatocytes before conventional liver function tests become abnormal. Prescribers should consider using the lower tadalafil dose (10 mg rather than 20 mg) in MASH patients as a precautionary measure, especially those closer to F3 fibrosis.

Monitoring Recommendations for Co-Administration

Because resmetirom already requires hepatic monitoring, the incremental burden of adding tadalafil to the regimen is minimal.

Baseline and Ongoing Lab Monitoring

The Rezdiffra label mandates measurement of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin before initiating therapy, then periodically during treatment [1]. No additional laboratory monitoring is required for tadalafil co-administration. Standard liver panels already in place for resmetirom will capture any hepatotoxicity signal regardless of cause.

Clinical Monitoring Points

Prescribers should assess for: (1) headache frequency and severity during the first 4 to 6 weeks of co-administration, (2) any symptomatic hypotension (lightheadedness on standing), particularly in patients on concurrent antihypertensives, and (3) gastrointestinal symptoms, since both drugs can cause nausea and diarrhea.

When to Reconsider the Combination

If ALT exceeds 5 times the upper limit of normal during treatment, the Rezdiffra label recommends withholding the drug and investigating [1]. In that scenario, tadalafil (which undergoes hepatic metabolism) should also be reassessed. A patient whose liver function is deteriorating may require tadalafil dose reduction or temporary discontinuation until the cause is identified.

Dose Adjustment Guidance

No formal dose adjustment of either drug is required based on pharmacokinetic interaction data.

Resmetirom Dosing Remains Weight-Based

Resmetirom is dosed at 80 mg daily for patients weighing less than 100 kg and 100 mg daily for patients at or above 100 kg [1]. This dosing does not change with tadalafil co-administration.

Tadalafil Dosing in MASH Populations

For erectile dysfunction, tadalafil is dosed at 10 mg prior to sexual activity, adjustable to 20 mg or 5 mg based on efficacy and tolerability. The 2.5 mg to 5 mg daily dose is used for BPH or daily ED therapy [2]. In MASH patients with F2-F3 fibrosis who have preserved hepatic function (normal albumin, normal INR, no ascites), standard tadalafil dosing is reasonable. For patients with borderline hepatic function or those approaching cirrhosis, limiting tadalafil to 10 mg as needed (not daily) is prudent [2].

The Endocrine Society's 2018 guideline on testosterone therapy notes that PDE5 inhibitors are first-line pharmacotherapy for erectile dysfunction and should not be withheld based on theoretical drug interactions absent supporting clinical evidence [6]. This principle applies to the resmetirom combination.

Relevant Clinical Trial Data

MAESTRO-NASH: The Key Resmetirom Trial

The phase 3 MAESTRO-NASH trial randomized 966 adults with biopsy-confirmed MASH and F2-F3 fibrosis to resmetirom 80 mg, 100 mg, or placebo [5]. At week 52, MASH resolution without worsening of fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% of placebo (P<0.001 for both comparisons) [5]. Fibrosis improvement by at least one stage without MASH worsening was achieved by 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo [5].

The trial's safety database did not report specific signals with concurrent PDE5 inhibitor use, though concomitant medication data have not been published at the individual-drug level.

Tadalafil Hepatic Impairment Data

In a pharmacokinetic study of tadalafil in subjects with hepatic impairment (Child-Pugh Class A and B), tadalafil 10 mg exposure (AUC) was comparable to healthy subjects, supporting the 10 mg maximum dose recommendation rather than complete avoidance [2]. As the FDA label states: "For patients with mild or moderate hepatic impairment, the dose of CIALIS should not exceed 10 mg" [2].

Patient Counseling Points

Clear communication reduces unnecessary medication discontinuation. Patients starting resmetirom who already take tadalafil (or vice versa) should understand four practical points.

What to Tell the Patient

First, this combination does not carry a safety warning comparable to the nitrate-PDE5 inhibitor interaction. Second, headache may be more frequent during the first weeks of co-administration, and standard over-the-counter analgesics (acetaminophen) can be used. Third, patients should report any new or worsening lightheadedness, particularly if they are also taking blood pressure medications. Fourth, all scheduled liver function tests for resmetirom monitoring should be kept on time.

When to Contact the Prescriber

Patients should seek medical attention if they experience prolonged erection (priapism), sudden vision changes, or jaundice. These are not specific to the drug combination but reflect serious adverse events associated with tadalafil and resmetirom independently [1][2].

Special Populations

Older Adults

Both drugs are commonly used in patients over 65. Resmetirom clinical trials included patients aged 18 to 75 (median age approximately 56 in MAESTRO-NASH) [5]. No dose adjustment for age is specified for either drug, but renal function should be assessed since tadalafil dose reduction to 5 mg is recommended when creatinine clearance falls below 30 mL/min [2].

Patients on Concurrent CYP3A4 Inhibitors

If a MASH patient takes a moderate CYP3A4 inhibitor (such as diltiazem or erythromycin), both resmetirom and tadalafil exposure may increase. In this three-drug scenario, the CYP3A4 inhibitor is the driver of interaction, not the resmetirom-tadalafil pair. Tadalafil should be limited to 10 mg every 72 hours when combined with a strong CYP3A4 inhibitor [2].

Patients with Pulmonary Arterial Hypertension

Tadalafil at the 40 mg PAH dose (Adcirca) produces substantially higher plasma concentrations than the ED dose. While no specific interaction with resmetirom is expected even at 40 mg, the higher tadalafil exposure increases sensitivity to any potential hepatic metabolic change. PAH patients on Adcirca who start resmetirom should have liver function tests at baseline and at 4 weeks, consistent with standard Rezdiffra monitoring [1].